Abstract
The calcineurin inhibitors pimecrolimus and tacro-limus are important tools for long-term management of atopic dermatitis in childhood. These drugs are approved in Germany for the intermittent long-term treatment of moderate to severe (tacrolimus ointment) or mild to moderate (pime-crolimus cream) atopic dermatitis in children older than 2 years. Recent study results show that these agents are also effective in infants (aged 3-23 months) with atopic dermatitis. During the longterm treatment of children and infants with calcineurin inhibitors,the therapeutic success can be maintained and there is a continuous increase in the response rate. Long-term use of calcineurin inhibitors in atopic dermatitis is well tolerated locally and systemically, leads to reduction of disease flares and has a corticosteroid sparing effect.
| Translated title of the contribution | Long term management of childhood atopic dermatitis with calcineurin inhibitors |
|---|---|
| Original language | German |
| Journal | Hautarzt |
| Volume | 54 |
| Issue number | 5 |
| Pages (from-to) | 418-423 |
| Number of pages | 6 |
| ISSN | 0017-8470 |
| DOIs | |
| Publication status | Published - 01.05.2003 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
